McKesson Corporation (NYSE: MCK) outlined its long-term growth strategy and updated financial targets at its 2025 Investor Day in Irving, Texas. The company raised its Fiscal 2026 adjusted earnings per share guidance to $38.05–$38.55, up from $37.10–$37.90, and lifted its long-term adjusted EPS growth target to 13–16% from 12–14%.

Executives highlighted strategic priorities, including strengthening North American pharmaceutical distribution, expanding oncology and biopharma services, and advancing portfolio optimization with the planned separation of its Medical-Surgical business. McKesson also introduced new segment growth targets: 5–8% for North American Pharmaceutical, 13–16% for Oncology & Multispecialty, and 10–13% for Prescription Technology Solutions.

CEO Brian Tyler said the company’s operational discipline and portfolio strength position it to drive sustainable growth and shareholder value. McKesson will release its Q2 fiscal 2026 results on November 5, 2025.